Cryoport reports Q4 EPS (42c), consensus (31c)

Reports Q4 revenue $59.53M, consensus $58.56M. Cryoport (CYRX) held $261.7M in cash, cash equivalents, and short-term investments as of December 31, 2024. Jerrell Shelton, CEO of Cryoport, commented, “Cryoport ended 2024 with solid results across the company including total full year revenue of $228.4M, which was in-line with our expectations. We continued to see considerable revenue growth from our support of commercial Cell & Gene therapies where revenue rose 37% for the Q4 and 20% for the full year compared to the prior year periods.